These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9579378)

  • 1. Iron chelation therapy: the need for orally active drugs.
    Hoffbrand AV
    J Lab Clin Med; 1998 Apr; 131(4):290-1. PubMed ID: 9579378
    [No Abstract]   [Full Text] [Related]  

  • 2. An orally active iron chelator.
    Nathan DG
    N Engl J Med; 1995 Apr; 332(14):953-4. PubMed ID: 7877655
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
    Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
    Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic iron chelators and their potential side-effects.
    Singh S; Khodr H; Taylor MI; Hider RC
    Biochem Soc Symp; 1995; 61():127-37. PubMed ID: 8660390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelation with oral deferiprone in patients with thalassemia.
    Wonke B; Telfer P; Hoffbrand AV
    N Engl J Med; 1998 Dec; 339(23):1712; author reply 1713-4. PubMed ID: 9867540
    [No Abstract]   [Full Text] [Related]  

  • 6. Iron Chelation in Thalassemia Major.
    Borgna-Pignatti C; Marsella M
    Clin Ther; 2015 Dec; 37(12):2866-77. PubMed ID: 26519233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferiprone chelation therapy for thalassemia major.
    Galanello R; Campus S
    Acta Haematol; 2009; 122(2-3):155-64. PubMed ID: 19907153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
    Donovan JM; Plone M; Dagher R; Bree M; Marquis J
    Ann N Y Acad Sci; 2005; 1054():492-4. PubMed ID: 16339704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
    Olivieri NF; Brittenham GM; Matsui D; Berkovitch M; Blendis LM; Cameron RG; McClelland RA; Liu PP; Templeton DM; Koren G
    N Engl J Med; 1995 Apr; 332(14):918-22. PubMed ID: 7877649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.
    Ballas SK; Zeidan AM; Duong VH; DeVeaux M; Heeney MM
    Am J Hematol; 2018 Jul; 93(7):943-952. PubMed ID: 29635754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral iron-chelating therapy: the L1 experience.
    al-Refaie FN; Hoffbrand AV
    Baillieres Clin Haematol; 1994 Dec; 7(4):941-63. PubMed ID: 7881161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 10th International Conference on Oral Iron Chelators in the treatment of beta-thalassemia and other diseases and biomed meeting.
    Richardson DR
    Expert Opin Investig Drugs; 2000 May; 9(5):1151-4. PubMed ID: 11221651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R
    Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron chelation with oral deferiprone in patients with thalassemia.
    Grady RW; Giardina PJ
    N Engl J Med; 1998 Dec; 339(23):1712-3; author reply 1713-4. PubMed ID: 9867541
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron-chelation therapy with oral chelators in patients with thalassemia major.
    Uygun V; Kurtoglu E
    Hematology; 2013 Jan; 18(1):50-5. PubMed ID: 23321010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In search of the optimal iron chelation therapy for patients with thalassemia major.
    Berdoukas V; Wood J
    Haematologica; 2011 Jan; 96(1):5-8. PubMed ID: 21193427
    [No Abstract]   [Full Text] [Related]  

  • 19. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG
    Lancet; 2003 Jan; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K; Pyar K; Wonke B
    Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.